Drug Safety Settlement

A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013. Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice. The settlement is its largest-ever with a generic drugmaker over drug safety, according to the U.S. government. It includes $150 million in payments for a criminal fine and forfeiture and $350 million in payments for civil claims. REUTERS/Ajay Verma (INDIA - Tags: HEALTH BUSINESS)

Daiichi Sankyo says it was misled over Ranbaxy U.S. probes

Japanese drugmaker Daiichi Sankyo Co, which bought control of Ranbaxy Laboratories in 2008, said it believes unnamed former shareholders of the company hid information regarding U.S. regulatory probes into Ranbaxy.  Full Article 

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Bernanke Testimony

Bernanke Testimony

Bernanke says more progress needed before stimulus pullback.  Full Article 

Sensex Falls

Sensex Falls

Sensex falls for third day; L&T results spark worries.  Full Article 

Copper Shortage

Copper Shortage

Copper smelter closures put cable makers in tight spot.  Full Article 

Tax Avoidance

Tax Avoidance

Factbox: Apple, Amazon, Google and tax avoidance schemes.  Full Article 

Tracking India Gold

Tracking India Gold

Physical gold market awaits fresh import guidelines.  Full Article 

Earnings Season

Earnings Season

L&T looks overseas to offset weak home market  Full Article | Full Coverage 

Bank Acquisition

Bank Acquisition

Srei Infrastructure to buy Austrian bank unit - paper  Full Article 

Just Dial IPO

Just Dial IPO

Just Dial's 9.4 billion rupee IPO covered 11.6 times  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Gilead signs deals with Indian cos for low-cost HIV drug

Related Topics

Stocks

   
Track BSE Sectoral Indices

Track Markets: BSE Sectoral Indices

Track and analyse performance of all BSE sectoral indices and other global indices on a single page.   Full Coverage 

A man suffering from HIV/AIDS receives treatment at a drug de-addiction centre in the northeastern Indian city of Siliguri July 6, 2007. REUTERS/Rupak De Chowdhuri/files

A man suffering from HIV/AIDS receives treatment at a drug de-addiction centre in the northeastern Indian city of Siliguri July 6, 2007.

Credit: Reuters/Rupak De Chowdhuri/files

Thu Aug 2, 2012 7:20pm IST

REUTERS - Gilead Sciences Inc (GILD.O) signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.

Under deals with Ranbaxy Laboratories (RANB.NS), Strides Arcolab (STAR.NS) and Mylan Inc's (MYL.O) India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.

Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.

(Reporting by Shailesh Kuber; Editing by Viraj Nair)
Top News
Business
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.